IL224698A - Crystalline forms of factor inhibitor xa - Google Patents

Crystalline forms of factor inhibitor xa

Info

Publication number
IL224698A
IL224698A IL224698A IL22469813A IL224698A IL 224698 A IL224698 A IL 224698A IL 224698 A IL224698 A IL 224698A IL 22469813 A IL22469813 A IL 22469813A IL 224698 A IL224698 A IL 224698A
Authority
IL
Israel
Prior art keywords
crystalline form
patient
stroke
betrixaban
thrombosis
Prior art date
Application number
IL224698A
Other languages
English (en)
Hebrew (he)
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of IL224698A publication Critical patent/IL224698A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL224698A 2010-09-01 2013-02-13 Crystalline forms of factor inhibitor xa IL224698A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37933910P 2010-09-01 2010-09-01
US201161454396P 2011-03-18 2011-03-18
PCT/US2011/050057 WO2012031017A1 (en) 2010-09-01 2011-08-31 CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR

Publications (1)

Publication Number Publication Date
IL224698A true IL224698A (en) 2017-01-31

Family

ID=45773260

Family Applications (1)

Application Number Title Priority Date Filing Date
IL224698A IL224698A (en) 2010-09-01 2013-02-13 Crystalline forms of factor inhibitor xa

Country Status (13)

Country Link
US (1) US8946269B2 (cg-RX-API-DMAC7.html)
EP (1) EP2611779B1 (cg-RX-API-DMAC7.html)
JP (4) JP2013536864A (cg-RX-API-DMAC7.html)
CN (1) CN103261161B (cg-RX-API-DMAC7.html)
AR (1) AR082804A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011295909B2 (cg-RX-API-DMAC7.html)
CA (1) CA2810004C (cg-RX-API-DMAC7.html)
ES (1) ES2603084T3 (cg-RX-API-DMAC7.html)
IL (1) IL224698A (cg-RX-API-DMAC7.html)
NZ (1) NZ608442A (cg-RX-API-DMAC7.html)
PT (1) PT2611779T (cg-RX-API-DMAC7.html)
TW (1) TW201221128A (cg-RX-API-DMAC7.html)
WO (1) WO2012031017A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980876B2 (en) 2010-10-28 2015-03-17 The Procter & Gamble Company Inhibition of microbial growth by aconitase inhibition
WO2013033370A1 (en) * 2011-08-31 2013-03-07 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
TWI502689B (zh) * 2012-03-16 2015-10-01 Luxtera Inc 光子材料中介層的方法及系統
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104693114B (zh) * 2013-12-10 2019-08-16 四川海思科制药有限公司 一种贝曲西班的改进的制备方法
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
WO2017091757A1 (en) * 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN106995405A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种贝曲西班马来酸盐无定型物及其制备方法
US20190300483A1 (en) * 2016-06-02 2019-10-03 Dr. Reddy's Laboratories Limited POLYMORPHS OF BETRlXABAN & ITS MALEATE SALT
EP3254674A1 (en) 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
EP3293174A1 (en) 2016-09-09 2018-03-14 Sandoz Ag Crystalline salts of betrixaban
WO2018069936A1 (en) * 2016-10-13 2018-04-19 Mylan Laboratories Limited Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof
CN107382897B (zh) * 2017-07-10 2021-05-04 浙江宏元药业股份有限公司 一种贝曲西班的中间体及其制备方法和应用
EP3510996A1 (en) * 2018-01-11 2019-07-17 Sandoz AG Pharmaceutical compositions of betrixaban
CN108570003A (zh) * 2018-06-01 2018-09-25 浙江宏元药业股份有限公司 一种贝曲西班马来酸盐的一水无定形及其制备方法
WO2020264076A1 (en) 2019-06-28 2020-12-30 The Procter & Gamble Company Light augmented treatment method

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
CA2565437A1 (en) 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
US7598276B2 (en) 2005-11-08 2009-10-06 Millenium Pharmaceuticals, Inc. Pharmaceutical salts and polymorphs of a factor Xa inhibitor
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
US20080051578A1 (en) 2006-08-24 2008-02-28 Georg Dahmann Substituted biaryls, process for their manufacture and use thereof as medicaments
PT2404906E (pt) 2006-11-02 2015-11-02 Millennium Pharm Inc Métodos de sintetizar sais farmacêuticos de um inibidor de fator xa
PT2101760E (pt) 2006-12-08 2013-05-07 Millennium Pharm Inc Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa
JP2010515691A (ja) 2007-01-05 2010-05-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 第Ｘａ因子阻害剤
EP2155195B1 (en) 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
NZ581324A (en) * 2007-05-02 2012-05-25 Portola Pharm Inc Combination therapy with a compound acting as a platelet adp receptor inhibitor
EP3824902A1 (en) 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CN102316893B (zh) 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
JP5766204B2 (ja) * 2009-12-17 2015-08-19 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 第Ｘａ因子阻害剤の合成方法
TW201240664A (en) 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor

Also Published As

Publication number Publication date
CN103261161A (zh) 2013-08-21
AU2011295909A1 (en) 2013-04-04
AR082804A1 (es) 2013-01-09
PT2611779T (pt) 2016-11-21
TW201221128A (en) 2012-06-01
US20120071519A1 (en) 2012-03-22
ES2603084T3 (es) 2017-02-23
JP2015232046A (ja) 2015-12-24
NZ608442A (en) 2015-04-24
JP2019135258A (ja) 2019-08-15
AU2011295909B2 (en) 2015-05-21
CA2810004A1 (en) 2012-03-08
JP2018024709A (ja) 2018-02-15
US8946269B2 (en) 2015-02-03
JP2013536864A (ja) 2013-09-26
CN103261161B (zh) 2016-04-27
WO2012031017A1 (en) 2012-03-08
CA2810004C (en) 2019-09-10
EP2611779B1 (en) 2016-08-10
EP2611779A1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
AU2011295909B2 (en) Crystalline forms of a factor Xa inhibitor
AU2006311544B2 (en) Pharmaceutical salts and polymorphs of N- (5-CHLORO-2-PYRIDINYL) -2- [ [4- [ (DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO] -5-METH OXY-BENZAMIDE, a factor XA inhibitor
JP6154473B2 (ja) 第ＸＩａ因子阻害剤の結晶形
HK1186181B (en) Crystalline forms of a factor xa inhibitor
MX2008005143A (en) Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl]benzoyl]amino]-5-meth oxy-benzamide, a factor xa inhibitor
HK1168594A (en) Method of preparing a factor xa inhibitor
HK1115131B (en) Pharmaceutical salts and polymorphs of n-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide , a factor xa inhibitor

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed